RealSeq Biosciences specializes in RNA fragmentomics, leveraging its proprietary RiboMarker® platform to discover novel RNA biomarkers that enhance diagnostic capabilities across various fields, including oncology, infectious diseases, and agricultural biotechnology. The RiboMarker platform utilizes advanced techniques such as library construction, next-generation sequencing (NGS), and AI-driven bioinformatics to analyze RNA fragments that traditional methods often overlook. This innovative approach allows for the detection of over 90% of circulating RNA fragments, providing deeper insights into disease progression and health states, which can significantly improve patient outcomes and diagnostic accuracy.

In addition to the RiboMarker platform, RealSeq offers a range of RNA NGS products and services, including specialized library preparation kits designed for low-concentration RNA samples from biofluids. Their technology minimizes detection bias through a patented single-adapter and circularization method, enhancing the reliability of RNA fragment detection. RealSeq's commitment to advancing RNA fragmentomics is evident in their focus on developing diagnostic applications that can track disease dissemination and response to treatment, ultimately aiming to improve the quality of life for patients and contribute to agricultural advancements.

United States

RealSeq Biosciences’ core expertise includes innovative proprietary technologies for bias-free small RNA/miRNA NGS library construction, targeted NGS tools, and cf-RNA analysis (liquid biopsy) that form the basis of the Company’s life science research programs and product development.

RealSeq Biosciences

Company Details